

# L-NMMA acetate

**Catalog No: tcsc0014213**



## Available Sizes

---

**Size:** 10mg

**Size:** 25mg

**Size:** 50mg

**Size:** 100mg



## Specifications

---

**CAS No:**

53308-83-1

**Formula:**

$C_9H_{20}N_4O_4$

**Pathway:**

Immunology/Inflammation

**Target:**

NO Synthase

**Purity / Grade:**

>98%

**Solubility:**

H<sub>2</sub>O : ≥ 50 mg/mL (201.39 mM)

**Alternative Names:**

Tilarginine acetate;Methylarginine acetate

**Observed Molecular Weight:**


248.28

## Product Description

L-NMMA acetate is a **nitric oxide synthase** inhibitor of all NOS isoforms including NOS1, NOS2, and NOS3. The **K<sub>i</sub>** values for nNOS (rat), eNOS (human), and iNOS (mouse) are approximately 0.18, 0.4, and 6 μM, respectively.

IC50 & Target: K<sub>i</sub>: 0.18 μM (nNOS), 0.4 μM (eNOS), 6 μM (iNOS)<sup>[1]</sup>

**In Vitro:** L-NMMA, starting from 100 μM, produces a concentration-dependent inhibition of the evoked relaxations (2Hz); maximal inhibition at 1 mM averaged about 35%. The inhibitory effect of L-NMMA is unchanged by previous incubation with D-arginine while it is prevented by L-arginine (L-Arg). L-NMMA does not affect isoprenaline-induced relaxation<sup>[2]</sup>. Superfusion of L-NMMA reduces arteriolar diameter and causes dose-dependent increases in arteriolar tone. The onset of action of L-NMMA is nearly immediate. L-NMMA inhibits vasodilator responses to the endothelium-dependent vasodilator ACh but not to the endothelium-independent NP. NE induced dose-related vasoconstriction that is significantly potentiated by L-NMMA<sup>[3]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!